ACS infectious diseases · 2023
Strigolactones as Broad-Spectrum Antivirals against β-Coronaviruses through Targeting the Main Protease Mpro.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biolatti Matteo, Blangetti Marco, Baggieri Melissa, Marchi Antonella, Gioacchini Silvia, Bajetto Greta, Arnodo Davide, Bucci Paola, Fioravanti Raoul, Kojouri Maedeh, Bersani Matteo, D'Arrigo Giulia, Siragusa Lydia, Ghinato Simone, De Andrea Marco, Gugliesi Francesca, Albano Camilla, Pasquero Selina, Visentin Ivan, D'Ugo Emilio, Esposito Francesca, Malune Paolo, Tramontano Enzo, Prandi Cristina, Spyrakis Francesca, Magurano Fabio, Dell'Oste Valentina
Аннотация
The current SARS-CoV-2 pandemic and the likelihood that new coronavirus strains will emerge in the immediate future point out the urgent need to identify new pan-coronavirus inhibitors. Strigolactones (SLs) are a class of plant hormones with multifaceted activities whose roles in plant-related fields have been extensively explored. Recently, we proved that SLs also exert antiviral activity toward herpesviruses, such as human cytomegalovirus (HCMV). Here we show that the synthetic SLs TH-EGO and EDOT-EGO impair β-coronavirus replication including SARS-CoV-2 and the common cold human coronavirus HCoV-OC43. Interestingly, in silico simulations suggest the binding of SLs in the SARS-CoV-2 main protease (Mpro) active site, and this was further confirmed by an in vitro activity assay. Overall, our results highlight the potential efficacy of SLs as broad-spectrum antivirals against β-coronaviruses, which may provide the rationale for repurposing this class of hormones for the treatment of COVID-19 patients.